Canada, and other countrywide groups. Also a number of academic societies such as European Society for Therapeutic Radiation Oncology, European Society of Surgical Oncology, European Society of Medical Oncology and European Society of Paediatric Oncology. In order to follow changing regulatory requirements, the EORTC regularly converses with the US Food and Drug Administration and the European Medicines Evaluation Agency. Figures Over 700 universities or affiliated hospitals in 27 countries Over 3500 collaborators (Medical Oncologists, Radiation Oncologists, Organ Specialists, Surgical Oncologists, Imaging Specialists) Over 198,000 patients in the EORTC database Results The EORTC has designed new benchmark treatments, in particular for: Improving the survival of patients with testicular cancer, Hodgkin's lymphoma, leukemia (child or adult), gastrointestinal stromal tumor, brain tumor, etc. Avoiding a laryngectomy for 42% of patients with larynx cancer Carrying out surgery which is less mutilating in the case of breast cancer Improving the quality of life for patients (ambulatory care, fertility preservation, etc.) Effectively controlling infections for patients with leukemia, etc. Funding EORTC Cancer Research Fund (ECRF) The EORTC Cancer Research Fund (ECRF) was created in 1976 to collect the necessary funds for the EORTC to function with the cooperation of national cancer leagues involved in the fight against cancer (Germany, Belgium, Denmark, France, Hong Kong, Norway, The Netherlands, The UK, Switzerland, Sweden, etc.). Princess Dina Mired of Jordan is the Honorary President and Count Diego du Monceau de Bergendal chairs the Board of Directors of the ECRF. Transparent and diversified financing EORTC research is supported by the EORTC Cancer Research Fund (ECRF), the National Cancer Institute (NCI) of the United States of America, Fonds Cancer (FOCA), and the Belgian National Lottery. The European Commission provides support only for selected projects. Partnerships with the pharmaceutical industry have been set up within the framework of special studies approved by an independent peer review committee. Nevertheless, more than 70% of clinical studies led by the EORTC focus on drugs that have already been commercialized or on combined strategies such as radiotherapy and surgery and consequently these studies require financial support from other sources. Additional contributions and sponsorship are vital to cover these scientific activities where the main goal is to effectively promote European cancer clinical research. Main scientific events and methodology courses EORTC Groups Annual Meeting (EGAM), biyearly conference EORTC - NCI - AACR Symposium on Molecular Targets and Cancer Therapeutics, biyearly conference European Breast Cancer Conference - EBCC as